Similarly, in a murine model of B cell lymphoma, the therapeutic effect of both PD-1 and CTLA-4 blockade was fully abrogated after ablation of IFN-γ (Ahmetlic et al., 2021). This evidence concerns the gene PDCD1 and B-cell non-Hodgkin lymphoma.